Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster “HER2 Functionalized Nanoparticles Are Safe and Specific for in
Click play icon ▶️ to listen (transcript follows below): As a sought-after medical imaging industry thought leader, Mike Harsh sat for a recorded interview by
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster “Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles” at the 2018
The ASCO 2018 Annual Meeting abstract, “Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry” is now available
“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017
The 2017 International Convention of BIO, the Biotechnology Innovation Organization, was held June 19-22 in San Diego. More than 16,000 individuals attended BIO 2017, including
On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled
On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public offering on
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
For effective use in detecting specific types of cancer, tumor-targeting nanoparticles must evade the immune system, remain intact for a clinically relevant time frame, and
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance